MiNK Therapeutics (INKT) Stock Aiming For T-Cell Treatment Breakthrough
Wasim Omar
September 23, 2022
MiNK Therapeutics (NASDAQ: INKT) is one of the only biopharmaceutical companies that has gone all in, in regards to invariant natural killer T cells (iNKT)